Yan Bruce Yin

Develop business in the life sciences and healthcare sectors, focusing on drug discovery, CRO (Contract Research Organization), and academic markets. Meso Scale Discovery (MSD) is a life sciences company specializing in highly sensitive, multiplex biomarker detection technologies, primarily serving drug development and biomedical research. MSD's core technology is Electrochemiluminescence (ECL), which offers high sensitivity, a broad dynamic range, and low background noise—ideal for quantifying proteins, cytokines, and other biomarkers. Its product portfolio includes multiplex assay kits, immunoassay instruments (such as the MESO SECTOR series), custom assay services, and supporting reagents. MSD’s platform is widely used in the pharmaceutical, biotechnology, and academic sectors, playing a key role in drug screening, toxicology, biomarker validation, and both preclinical and clinical studies. By enabling reliable, high-throughput, and high-quality data generation, MSD helps accelerate the research and development process. Renowned for its sensitivity and flexibility, MSD is a trusted partner in the field of bioanalytical research.

• Developed CRO Business of Covance with Pharmaceutical and Biotech companies in China, focusing on preclinical toxicology, DMPK, animal model, and clinical bioanalytical testing services. • Managed annual marketing budgets and pricing strategies, reporting directly to the APAC GM. • Successfully increased revenue through strategic partnerships and client acquisitions in the pharmaceutical and biotech sectors. • Coordinated clinical department and central lab across the US, Korea, Japan, and China to support FDA/EMEA/CFDA filings. Covance (now known as Labcorp Drug Development) is a leading global contract research organization (CRO) and a subsidiary of Labcorp. Its core business spans the entire drug development process, including preclinical research, clinical trial management, bioanalysis, regulatory affairs support, and patient recruitment. With a vast network of laboratories and clinical sites worldwide, the company supports everything from early-stage drug screening to Phase I–IV clinical trials, helping biopharmaceutical companies accelerate the development of new therapies. Its services cover a wide range of therapeutic areas, including oncology, immunology, central nervous system disorders, and rare diseases. Leveraging deep industry expertise, advanced technology platforms, and global resources, Labcorp Covance provides customized, end-to-end development solutions for pharmaceutical, biotechnology, and medical device companies.

• Managed national sales and marketing teams to develop market strategies and client training, meeting revenue targets. • Integrated brand resources (R&D Systems, Tocris, Medix) and optimized CRM/ERP systems to enhance customer outreach efficiency. • Achieved revenue growth and margin targets through strategic planning and competitor analysis. • Managed logistic process from US to China and built relationship with China customs. Bio-Techne is a global leader in the life sciences industry, dedicated to providing high-quality products and services for research, diagnostics, and therapeutic development. Its main offerings include recombinant proteins, antibodies, ELISA kits, cell culture and separation reagents, molecular detection reagents, and small molecule compounds. These products are widely used in research fields such as cell biology, immunology, neuroscience, oncology, and regenerative medicine. Bio-Techne owns several well-known brands, including R&D Systems, Novus Biologicals, Tocris, ProteinSimple, and Advanced Cell Diagnostics (ACD), covering all stages from basic research to clinical translation. The company’s products support scientists, diagnostic developers, and biopharmaceutical companies around the world.

• Exported chemicals and pharmaceutical raw materials from China to global pharmaceutical companies. • Secured the first European client and closed the company’s inaugural European deal, establishing overseas client acquisition processes. • Utilized email marketing, trade shows, and contract negotiation to expand the company's client base.

Since 2023, the School of Life Sciences at Fudan University has launched the "Practical Entrepreneurship Program for the Biomedical and General Health Industry" with great fanfare. This program integrates multi - lateral resources to cultivate outstanding entrepreneurial CEOs with a solid scientific research foundation, as well as entrepreneurial capabilities and an industrial mindset.

The MBA degree education program jointly organized by East China University of Science and Technology and the University of Canberra in Australia is a Sino - foreign cooperative MBA program approved by the Ministry of Education of the People's Republic of China and the Academic Degrees Committee of the State Council. It was launched in 2000. Over the 25 - year history of the Program's operation, it has been equipped with excellent teaching staff. So far, it has nurtured more than 1,500 elites in the field of business administration, and has become a high - quality MBA program with influence radiating across the country.

It ranks the top of Austalian universities and receives five star recognition from the country.

National "Double First - Class" Initiative

National key universities approved by the State Council